From suburban lake to livable area, then to a sci-tech innovation hub… South of Wuhan, in Jiangxia District, embracing the 47.6-square-kilometer Tangxun Lake—known as “Asia’s largest urban lake”—a profound transformation is continuously unfolding.
Over the past three years, the number of high-tech enterprises has been rising steadily, over 100,000 young talents have settled here, and invention patents have grown rapidly… It has been observed that, leveraging Tangxun Lake, a sci-tech innovation hub with an emerging “rainforest-like” innovation ecosystem and a concentration of various innovation elements is thriving.
Three Years, 100,000 Young Talents Settled
Research Institutes, Innovation Platforms, and Universities Gather Around Tangxun Lake, Driving a Surge of Innovation “Source Water”
Various innovation elements gather by Tangxun Lake.
On August 22, at the Tangxun Lake Institute of Light Quantum Research, “post-90s” research backbone Shen Chuyang was leading his team in debugging a self-developed quantum gravity gradiometer.
He vividly explained its value: “It’s like giving the Earth a ‘CT scan.’ Changes in gravity reveal density differences underground; whether deeply buried minerals or hidden geological faults or active zones, nothing escapes its ‘keen eye.'” This technology holds significant importance for deep-earth resource exploration, geological disaster warning, earthquake monitoring, and other fields. In 2020, after earning his Ph.D. from Tsinghua University, Shen Chuyang came to Jiangxia to engage in scientific research. “Jiangxia has a beautiful environment and a strong innovation atmosphere. Working here inspires scientific research ideas,” he said, gazing at the shimmering lake outside the window.
Echoing this is the brightly lit Jiangxia Laboratory. On August 12, the laboratory released three major scientific and technological achievements, one of which was the successful development of a new bispecific antibody drug for treating hemophilia A. While its efficacy is highly comparable to the original drug, its formulation technology breaks through the original patent, with a robust and quality-controllable preparation process, and the patient’s medication cost is only 25% of the original drug. This drug has achieved stable mass production on a commercial scale and is about to apply for clinical registration,有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首仿品种有望成为全球首
